Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Stocks hitting 52-week highs on April 25)
- Eleven Biotherapeutics Inc (NASDAQ:EBIO)
- Integra Lifesciences Holdings Corp (NASDAQ:IART) (on a beat-and-raise quarter)
Down In The Dumps
(Stocks hitting 52-week lows on April 25)
Stocks In Focus
Eloxx To Begin Trading On Nasdaq
Eloxx Pharmaceuticals Inc (NASDAQ:ELOX) shares, which were trading on the OTC, will begin to trade on the Nasdaq under the ticker symbol "ELOX" on Thursday. The company also announced it has priced its underwritten public offering of 5.13 million shares at $9.75 per share.
Catabasis Releases Positive DMD Phase 2 Trial Results
The stock was up 14 percent at $1.85.
Biomarin Reports Wider-than-Expected Q1 Loss
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), which specializes in enzyme replacement therapy, reported Q1 loss of 26 cents per share compared to a loss of 9 cents per share a year ago. Analysts, on average, estimated a loss of 18 cents per share. Revenues rose about 23 percent to $373.45 million, and exceeded the consensus estimate. The stock fell 1.39 percent to $18.40.
On The Radar
The following companies report earnings on Thursday:
FDA Tidbits
The FDA is clamping down on e-cigar maker Juul Labs, with Commissioner Scott Gottlieb announcing new enforcement actions and a "Youth Tobacco Prevention Plan" to prevent youth from accessing e-cigars. According to TechCrunch, Juul Labs has about half of the $2 billion market for e-cigars.
Related Links:
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
